Article

Novartis to market antibody fragment

Basel, Switzerland-Novartis Ophthalmics will have exclusive license to develop and market ranibizumab (Lucentis, formerly known as rhuFab V2), an anti-VEGF antibody fragment, outside North America under a new agreement with Genentech Inc.

Related Videos
Dr. Analisa Arosemena discusses glaucoma at EyeCon 2024
Dr. Amir Ghanipour discusses light adjustable lenses for cataracts at EyeCon 2024
EyeCon 2024: Adam Wenick, MD, talks about myopic interventions across the lifespan
Related Content
ASU researchers tap AI to help people see more clearly
October 7th 2024

ASU researchers tap AI to help people see more clearly

Ehsan Sadri, MD, and Colin Green, PhD: How a noninvasive eye drop therapy could transform keratoconus care
September 23rd 2024

Innovation Series: What a noninvasive eye drop approach may mean for the future of keratoconus

World Sight Day 2024: Patients urged to ‘Love Your Eyes’
October 7th 2024

World Sight Day 2024: Patients urged to ‘Love Your Eyes’

Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics
August 30th 2024

Latest advances in X-linked retinitis pigmentosa: Optimizing diagnosis and developments in gene therapy

Small hyperreflective retinal foci: An in vivo imaging feature of resident microglia activation in geographic atrophy
October 5th 2024

Small hyperreflective retinal foci: An in vivo imaging feature of resident microglia activation in geographic atrophy

Researchers: New AI model reaches clinical-expert-level accuracy in complex medical scans
October 4th 2024

Researchers: New AI model reaches clinical-expert-level accuracy in complex medical scans

© 2024 MJH Life Sciences

All rights reserved.